Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared a post on LinkedIn:
“How to treat patients with metastatic breast cancer after prior exposure to T-DXd?
We conducted a large (~800 pts) retrospective analysis using the Flatiron database to unveil the performance of different treatment regimens used immediately after T-DXd.
We found that:
- changing mechanism of action of the post-T-DXd treatment works best (rwPFS 4-6 months with capecitabine, eribulin, endocrine treatment)
- using SG after T-DXd led to rwPFS ≤3 months across subtypes, both if used immediately or after an intermediate line of chemo
- better outcomes with SG were observed in patients that discontinued T-DXd in the absence of progression, or that were on prior T-DXd for a short time.”
Title: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
Authors: Paolo Tarantino, Do Lee, Julia Foldi, Pamela R. Soulos, Cary P. Gross, Tess O’Meara, Thomas Grinda, Stefania Morganti, Adrienne G. Waks, Eric P. Winer, Nancy U. Lin, Ian E. Krop, Sara M. Tolaney, Sarah Sammons, Maryam Lustberg
Read the Full Article.
More posts featuring Paolo Tarantino.
